DETAILED NOTES ON SITUS JUDI MBL77

In addition to ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and healthy ample to tolerate FCR therapy, should still be very good candidates for the latter, Along with the advantage getting this cure might be done in 6 months when ibrutinib needs to be taken indefinitely. This selection can be especially important for non-compliant